{"symbol":"BMY","fiscalQuarter":"Q2-2013","reportDate":"2013-07-25","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2013","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 1.48%","keyNumbers":[{"metric":"EPS","actual":"$0.44","expected":"N/A","surprise":"+1.15%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing commitment to innovation.","They acknowledged challenges in the market but expressed confidence in pipeline products."],"summary":"Management conveyed a cautious optimism about future growth despite current market challenges. They emphasized their focus on innovation and product development."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report shows a slight beat on EPS, which indicates some positive momentum. However, the stock fell by 1.48%, likely due to the lack of revenue details and no updated guidance. Investors may be concerned about the company's future performance without clearer financial expectations.","metaDescription":"Bristol Myers Squibb (BMY) Q2 2013 earnings: EPS beat by 1.15%. Stock down 1.48%. Full breakdown."}}